Shares of Diploma PLC (LON:DPLM – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is GBX 7,400.
Several equities analysts have recently commented on DPLM shares. Jefferies Financial Group restated a “hold” rating and set a GBX 7,000 price target on shares of Diploma in a report on Friday, May 29th. Berenberg Bank reissued a “buy” rating and set a GBX 9,000 price objective on shares of Diploma in a research report on Monday, July 20th. Royal Bank Of Canada boosted their target price on Diploma from GBX 7,300 to GBX 7,400 and gave the company an “outperform” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. lifted their price target on Diploma from GBX 5,760 to GBX 8,250 and gave the company an “overweight” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Diploma from GBX 6,400 to GBX 7,200 and gave the company a “buy” rating in a research note on Wednesday, May 20th.
Check Out Our Latest Research Report on Diploma
Insider Buying and Selling at Diploma
Diploma Stock Up 1.5%
DPLM stock opened at GBX 7,290 on Monday. Diploma has a 12-month low of GBX 4,970 and a 12-month high of GBX 7,765. The company has a quick ratio of 0.80, a current ratio of 2.06 and a debt-to-equity ratio of 47.65. The company has a market cap of £9.78 billion, a price-to-earnings ratio of 51.78, a PEG ratio of 2.82 and a beta of 0.92. The company has a 50 day moving average of GBX 7,227.28 and a two-hundred day moving average of GBX 6,585.94.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Articles
- Five stocks we like better than Diploma
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
